{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:36:18Z","timestamp":1773099378018,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Patient characteristics and platelet responses at romiplostim initiation according to the duration of immune thrombocytopenia (ITP) are poorly understood. Amongst romiplostim\u2010exposed adults with ITP lasting \u22656\u2009months during 2009\u20132018 in Denmark, Sweden, and Norway, we examined characteristics at romiplostim initiation, romiplostim dosage, and durable platelet response (\u226575% of measurements \u226550\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L at 14\u201324\u2009weeks) for subcohorts with newly diagnosed (duration &lt;3\u2009months), persistent (3\u201312\u2009months), or chronic (&gt;12\u2009months) ITP initiating romiplostim. The 285 romiplostim initiators comprised 81 (28%) with newly diagnosed, 47 (16%) with persistent, and 157 (55%) with chronic ITP. More patients with newly diagnosed ITP than longer ITP duration, had low comorbidity levels, two or more prior ITP therapies, and previous bleeding requiring hospitalisation. The median romiplostim doses were similar across subcohorts. During treatment, median platelet counts were similar across subcohorts (75\u201376\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L), and the durable platelet response was 64.6%, 52.9%, and 52.7% for newly diagnosed, persistent, and chronic ITP, respectively. After treatment cessation, the median platelet count was 138\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L, 68\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L, and 71\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L, respectively. In conclusion, newly diagnosed patients, compared with romiplostim initiators with longer disease duration, had more severe ITP, higher frequency of durable platelet response, and higher median platelet count after cessation.<\/jats:p>","DOI":"10.1111\/bjh.19688","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:35:51Z","timestamp":1722886551000},"page":"1497-1507","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway"],"prefix":"10.1111","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0727-953X","authenticated-orcid":false,"given":"Christian Fynbo","family":"Christiansen","sequence":"first","affiliation":[{"name":"Department of Clinical Epidemiology Aarhus University Hospital and Aarhus University  Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nickolaj","family":"Risbo","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology Aarhus University Hospital and Aarhus University  Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-6165","authenticated-orcid":false,"given":"Waleed","family":"Ghanima","sequence":"additional","affiliation":[{"name":"Department of Medicine \u00d8stfold Hospital Trust  Gr\u00e5lum Norway"},{"name":"Department of Hematology Oslo University Hospital and Institute of Clinical Medicine, University of Oslo  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Linder","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division and Centre for Pharmacoepidemiology, Department of Medicine Karolinska Institutet  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahram","family":"Bahmanyar","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division and Centre for Pharmacoepidemiology, Department of Medicine Karolinska Institutet  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anouchka","family":"Seesaghur","sequence":"additional","affiliation":[{"name":"Center for Observational Research, Amgen  Uxbridge UK"},{"name":"Center for Observational Research, Amgen  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Clouser","sequence":"additional","affiliation":[{"name":"Center for Observational Research, Amgen  Uxbridge UK"},{"name":"Center for Observational Research, Amgen  Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mette","family":"N\u00f8rgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology Aarhus University Hospital and Aarhus University  Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik Toft","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology Aarhus University Hospital and Aarhus University  Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1810479"},{"key":"e_1_2_10_3_1","volume-title":"FDA drug safety communication: modified risk evaluation and mitigation strategies (REMS) for Nplate (romiplostim) and Promacta (eltrombopag)","author":"US FDA","year":"2011"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000966"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13827"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000812"},{"key":"e_1_2_10_8_1","unstructured":"European Medicines Agency.Nplate \u2013 Summary of Product Characteristics [Internet]. 2009 [Updated 17 October 2022]. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/nplate\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1850253"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.1948209"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15803"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000726"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01727-5"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000521689"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05289-0"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.07.015"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S314959"},{"issue":"23","key":"e_1_2_10_18_1","first-page":"2867","article-title":"Prolonged response after TPO\u2010RA discontinuation in primary ITP: results of a prospective multicenter study","volume":"141","author":"Guillet S","year":"2023","journal-title":"Blood"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13221"},{"issue":"8","key":"e_1_2_10_20_1","first-page":"1041","article-title":"The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy","volume":"91","author":"Sailer T","year":"2006","journal-title":"Haematologica"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T08:33:12Z","timestamp":1758097992000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/bjh.19688"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19688","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"2023-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}